Pierre Fabre signs XtalPi agreement for AI and robotics drug discovery
Image: Primary Laboratoires Pierre Fabre and XtalPi announced an agreement on November 9 to discover small-molecule drug candidates across multiple research programs in oncology, potentially dermatology, and rare diseases. XtalPi will use AI and robotics to design new molecules against undisclosed targets.
Pierre Fabre will select and advance promising compounds and take responsibility for subsequent clinical and commercial development. The agreement includes an upfront payment, multiple milestone payments and downstream economic participation; the companies did not disclose specific financial terms.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from Yahoo Finance and reviewed by the T&B editorial agent team.
Back to Newswire
